Delphinidin modulates the DNA-damaging properties of topoisomerase II poisons

Chem Res Toxicol. 2009 Mar 16;22(3):554-64. doi: 10.1021/tx800293v.

Abstract

The anthocyanidin delphinidin (DEL) has recently been shown to inhibit human topoisomerase I and II, without stabilizing the covalent DNA/topoisomerase intermediate [Habermeyer, M., Fritz, J., Barthelmes, H. U., Christensen, M. O., Larsen, M. K., Boege, F., and Marko, D. (2005) Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity. Chem. Res. Toxicol. 18, 1395-404]. In the present study, we demonstrated that DEL affects the catalytic activity of topoisomerase IIalpha in a redox-independent manner. Furthermore, this potent inhibitory effect is not limited to a cell-free system, but is also of relevance within intact cells. DEL at micromolar concentrations was found to significantly decrease the level of topoisomerase IIalpha/DNA intermediates stabilized by the topoisomerase II poison doxorubicin in the human colon carcinoma cell line (HT29). In addition, DEL diminished the DNA-damaging properties of topoisomerase II poisons in HT29 cells without affecting the level of sites sensitive to formamidopyrimidine-DNA-glycosylase. However, the preventive effect on DNA damage exhibited an apparent maximum at a concentration of 10 microM DEL, followed by a recurrence of DNA damage at higher DEL concentrations. Furthermore, the incubation of HT29 cells with 10 microM DEL resulted in a decrease of etoposide (ETO)-induced DNA strand breaks. However, the level of ETO-stabilized covalent topoisomerase/DNA intermediates did not affect DEL, indicating an additional mechanism of action. An impact of DEL on genes involved in the repair of DNA double-strand breaks and the onset of apoptosis has to be considered. In conclusion, the natural food constituent DEL represents, depending on the concentration range, a protective factor against the DNA-damaging effects of topoisomerase II poisons in vitro. Further studies are needed to clarify whether in vivo a high DEL intake might compromise the therapeutic outcome of these anticancer agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthocyanins / pharmacology*
  • Antigens, Neoplasm
  • DNA Damage / drug effects*
  • DNA Topoisomerases, Type II
  • DNA-Binding Proteins / antagonists & inhibitors*
  • Doxorubicin / antagonists & inhibitors
  • Doxorubicin / chemistry
  • Doxorubicin / toxicity
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / toxicity*
  • Etoposide / antagonists & inhibitors
  • Etoposide / chemistry
  • Etoposide / toxicity
  • HT29 Cells
  • Humans
  • Molecular Structure

Substances

  • Anthocyanins
  • Antigens, Neoplasm
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • Etoposide
  • Doxorubicin
  • DNA Topoisomerases, Type II
  • delphinidin